We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMMTFB
Motif Bio PLC
14 June 2017
Motif Bio plc
("Motif Bio" or the "Company")
Presentation at BIO International Convention
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at BIO 2017 being held at the San Diego Convention Center, 111 West Harbor Drive, San Diego from 19-22 June 2017.
The presentation will provide information on the progress of its novel antibiotic candidate, iclaprim, and will take place at 3.30pm on Wednesday, 21 June in Presentation Theater 3. The presentation will be available shortly after on the company website: www.motifbio.com
The BIO International Convention brings together over 16,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy - for more information see: http://convention.bio.org
For further details please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Rob Dickey (Chief Financial Officer) Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900 Dr. Christopher Golden Oliver Jackson Northland Capital Partners Limited (BROKER) +44 (0)20 3861 6625 Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or PR & IR) motifbio@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893 Mike Wort Mob: +44 (0)7900 608 002 MC Services AG (EUROPEAN IR) +49 (0)89 210 2280 Raimund Gabriel
About Motif Bio: www.motifbio.com
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMVKFZGNZM
(END) Dow Jones Newswires
June 14, 2017 02:00 ET (06:00 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
